{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:25:10Z","timestamp":1792801510613,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-511x-13-67","type":"journal-article","created":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T09:02:25Z","timestamp":1397725345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia"],"prefix":"10.1186","volume":"13","author":[{"given":"Congwu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChengXu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,17]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.2014.110","volume":"311","author":"VM Montori","year":"2014","unstructured":"Montori VM, Brito JP, Ting HH: Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA. 2014, 311: 465-466. 10.1001\/jama.2014.110","journal-title":"JAMA"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, op Reimer WJ S, Vrints C, Wood D, Zamorano JL, Zannad F: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 33: 1635-1701.","journal-title":"Eur Heart J"},{"key":"1061_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/HYPERTENSIONAHA.111.183210","volume":"59","author":"TB Domagala","year":"2012","unstructured":"Domagala TB, Szeffler A, Dobrucki LW, Dropinski J, Polanski S, Leszczynska-Wiloch M, Kotula-Horowitz K, Wojciechowski J, Wojnowski L, Szczeklik A, Kalinowski L: Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels. Hypertension. 2012, 59: 825-832. 10.1161\/HYPERTENSIONAHA.111.183210","journal-title":"Hypertension"},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1161\/CIRCULATIONAHA.113.002714","volume":"128","author":"H Xiao","year":"2013","unstructured":"Xiao H, Lu M, Lin TY, Chen Z, Chen G, Wang WC, Marin T, Shentu TP, Wen L, Gongol B, Sun W, Liang X, Chen J, Huang HD, Pedra JH, Johnson DA, Shyy JY: Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation. 2013, 128: 632-642. 10.1161\/CIRCULATIONAHA.113.002714","journal-title":"Circulation"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1161\/ATVBAHA.112.300749","volume":"33","author":"A Zechariah","year":"2013","unstructured":"Zechariah A, ElAli A, Hagemann N, Jin F, Doeppner TR, Helfrich I, Mies G, Hermann DM: Hyperlipidemia attenuates vascular endothelial growth factor-induced angiogenesis, impairs cerebral blood flow, and disturbs stroke recovery via decreased pericyte coverage of brain endothelial cells. Arterioscler Thromb Vasc Biol. 2013, 33: 1561-1567.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1161\/CIRCULATIONAHA.113.004243","volume":"128","author":"R Puri","year":"2013","unstructured":"Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ: C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013, 128: 2395-2403. 10.1161\/CIRCULATIONAHA.113.004243","journal-title":"Circulation"},{"key":"1061_CR7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jacc.2013.02.098","volume":"62","author":"PS Sever","year":"2013","unstructured":"Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N: Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol. 2013, 62: 717-729. 10.1016\/j.jacc.2013.02.098","journal-title":"J Am Coll Cardiol"},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/abbs\/gmr087","volume":"43","author":"A Cai","year":"2011","unstructured":"Cai A, Zheng D, Dong Y, Qiu R, Huang Y, Song Y, Jiang Z, Rao S, Liao X, Kuang J, Dai G, Mai W: Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction. Acta Biochim Biophys Sin (Shanghai). 2011, 43: 857-866. 10.1093\/abbs\/gmr087","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"1061_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mvr.2012.03.007","volume":"84","author":"C Ott","year":"2012","unstructured":"Ott C, Schneider MP, Schlaich MP, Schmieder RE: Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvasc Res. 2012, 84: 60-64. 10.1016\/j.mvr.2012.03.007","journal-title":"Microvasc Res"},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacl.2007.07.002","volume":"1","author":"PP Toth","year":"2007","unstructured":"Toth PP: Making a case for quantitative assessment of cardiovascular risk. J Clin Lipidol. 2007, 1: 234-241. 10.1016\/j.jacl.2007.07.002","journal-title":"J Clin Lipidol"},{"key":"1061_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2004.10.025","volume":"179","author":"P Turunen","year":"2005","unstructured":"Turunen P, Puhakka H, Rutanen J, Hiltunen MO, Heikura T, Gruchala M, Yla-Herttuala S: Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis. 2005, 179: 27-33. 10.1016\/j.atherosclerosis.2004.10.025","journal-title":"Atherosclerosis"},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ejlt.200300845","volume":"105","author":"A Constantinos","year":"2003","unstructured":"Constantinos A, Demopoulos Haralabos C, Karantonis Smaragdi A: Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Tech. 2003, 105: 705-716. 10.1002\/ejlt.200300845.","journal-title":"Eur J Lipid Sci Tech"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0025-6196(11)60992-0","volume":"82","author":"CA Garza","year":"2007","unstructured":"Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007, 82: 159-165. 10.1016\/S0025-6196(11)60992-0","journal-title":"Mayo Clin Proc"},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nm.1870","volume":"14","author":"RL Wilensky","year":"2008","unstructured":"Wilensky RL, Shi Y, Mohler ER, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008, 14: 1059-1066. 10.1038\/nm.1870","journal-title":"Nat Med"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jacc.2007.10.048","volume":"51","author":"LB Daniels","year":"2008","unstructured":"Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E: Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol. 2008, 51: 913-919. 10.1016\/j.jacc.2007.10.048","journal-title":"J Am Coll Cardiol"},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2796.2010.02297.x","volume":"269","author":"KC Epps","year":"2011","unstructured":"Epps KC, Wilensky RL: Lp-PLA(2)- a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011, 269: 94-106. 10.1111\/j.1365-2796.2010.02297.x","journal-title":"J Intern Med"},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1155\/2013\/432136","volume":"34","author":"A Cai","year":"2013","unstructured":"Cai A, Zheng D, Qiu R, Mai W, Zhou Y: Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013, 34: 323-331. 10.1155\/2013\/432136","journal-title":"Dis Markers"},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FJC.0b013e31820376ac","volume":"57","author":"JX Song","year":"2011","unstructured":"Song JX, Ren JY, Chen H: Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway. J Cardiovasc Pharmacol. 2011, 57: 213-222. 10.1097\/FJC.0b013e31820376ac","journal-title":"J Cardiovasc Pharmacol"},{"key":"1061_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0003319710375089","volume":"62","author":"N Tsantila","year":"2011","unstructured":"Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA: In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011, 62: 209-218. 10.1177\/0003319710375089","journal-title":"Angiology"},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/clc.20853","volume":"34","author":"SH Lee","year":"2011","unstructured":"Lee SH, Kang SM, Park S, Jang Y, Chung N, Choi D: The effects of statin monotherapy and low-dose statin\/ezetimibe on lipoprotein-associated phospholipase A(2). Clin Cardiol. 2011, 34: 108-112. 10.1002\/clc.20853","journal-title":"Clin Cardiol"},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00005344-200401000-00018","volume":"43","author":"J Beltowski","year":"2004","unstructured":"Beltowski J, Wojcicka G, Jamroz A: Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol. 2004, 43: 121-127. 10.1097\/00005344-200401000-00018","journal-title":"J Cardiovasc Pharmacol"},{"key":"1061_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/01.mol.0000174155.61307.5f","volume":"16","author":"CH Macphee","year":"2005","unstructured":"Macphee CH, Nelson JJ, Zalewski A: Lipoprotein-associated phospholipase A2 as a target of therapy. Curr Opin Lipidol. 2005, 16: 442-446. 10.1097\/01.mol.0000174155.61307.5f","journal-title":"Curr Opin Lipidol"},{"key":"1061_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL: Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013, 61: 404-410. 10.1016\/j.jacc.2012.10.027","journal-title":"J Am Coll Cardiol"},{"key":"1061_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/PL00007458","volume":"292","author":"K Modschiedler","year":"2000","unstructured":"Modschiedler K, Weller M, Worl P, Den Driesch PV: Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res. 2000, 292: 32-36. 10.1007\/PL00007458","journal-title":"Arch Dermatol Res"},{"key":"1061_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1476-511X-12-154","volume":"12","author":"YH Yang","year":"2013","unstructured":"Yang YH, Yang J, Jiang QH: Hypolipidemic effect of gypenosides in experimentally induced hypercholesterolemic rats. Lipids Health Dis. 2013, 12: 154- 10.1186\/1476-511X-12-154","journal-title":"Lipids Health Dis"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.metabol.2012.12.013","volume":"62","author":"O Schlager","year":"2013","unstructured":"Schlager O, Widhalm K, Hammer A, Giurgea A, Margeta C, Fritsch M, Zehetmayer S, Koppensteiner R, Gschwandtner ME, Willfort-Ehringer A: Familial hypercholesterolemia affects microvascular autoregulation in children. Metabolism. 2013, 62: 820-827. 10.1016\/j.metabol.2012.12.013","journal-title":"Metabolism"},{"key":"1061_CR27","volume-title":"J Pharm Pharmacol","author":"M Ahmed","year":"2014","unstructured":"Ahmed M, El Bakly WM, Zaki AM, Abd ALF, El SO: Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha.LID. J Pharm Pharmacol. 2014, doi:10.1111\/jphp.12213."},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359: 2195-2207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"key":"1061_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1172\/JCI66843","volume":"123","author":"JK Liao","year":"2013","unstructured":"Liao JK: Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 2013, 123: 540-541. 10.1172\/JCI66843","journal-title":"J Clin Invest"},{"key":"1061_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.coph.2005.11.008","volume":"6","author":"CH Macphee","year":"2006","unstructured":"Macphee CH, Nelson J, Zalewski A: Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2006, 6: 154-161. 10.1016\/j.coph.2005.11.008","journal-title":"Curr Opin Pharmacol"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s11095-012-0828-z","volume":"29","author":"Y Lu","year":"2012","unstructured":"Lu Y, Chen J, Xiao M, Li W, Miller DD: An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012, 29: 2943-2971. 10.1007\/s11095-012-0828-z","journal-title":"Pharm Res"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.105.602532","volume":"113","author":"U Forstermann","year":"2006","unstructured":"Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006, 113: 1708-1714. 10.1161\/CIRCULATIONAHA.105.602532","journal-title":"Circulation"},{"key":"1061_CR33","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","volume":"99","author":"M Nidorf","year":"2007","unstructured":"Nidorf M, Thompson PL: Effect of colchicine (0.5\u2009mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007, 99: 805-807. 10.1016\/j.amjcard.2006.10.039","journal-title":"Am J Cardiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-511X-13-67.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T19:52:59Z","timestamp":1548186779000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/1476-511X-13-67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,17]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1186\/1476-511x-13-67","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,17]]},"assertion":[{"value":"17 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"67"}}